California Public Employees Retirement System grew its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 10.0% in the 4th quarter, HoldingsChannel reports. The fund owned 4,481,229 shares of the biopharmaceutical company’s stock after acquiring an additional 405,700 shares during the period. California Public Employees Retirement System’s holdings in Bristol-Myers Squibb were worth $274,610,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Community Bank N.A. lifted its position in shares of Bristol-Myers Squibb by 6.3% during the fourth quarter. Community Bank N.A. now owns 37,693 shares of the biopharmaceutical company’s stock worth $2,309,000 after purchasing an additional 2,247 shares during the last quarter. Boston Family Office LLC lifted its position in shares of Bristol-Myers Squibb by 3.7% during the fourth quarter. Boston Family Office LLC now owns 42,352 shares of the biopharmaceutical company’s stock worth $2,595,000 after purchasing an additional 1,498 shares during the last quarter. Goelzer Investment Management Inc. lifted its position in shares of Bristol-Myers Squibb by 3.0% during the fourth quarter. Goelzer Investment Management Inc. now owns 77,347 shares of the biopharmaceutical company’s stock worth $4,740,000 after purchasing an additional 2,230 shares during the last quarter. MPI Investment Management Inc. bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $496,000. Finally, Teacher Retirement System of Texas lifted its position in shares of Bristol-Myers Squibb by 6.3% during the fourth quarter. Teacher Retirement System of Texas now owns 823,882 shares of the biopharmaceutical company’s stock worth $50,487,000 after purchasing an additional 48,729 shares during the last quarter. Institutional investors own 71.55% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other news, Director Theodore R. Samuels II purchased 4,000 shares of the company’s stock in a transaction on Friday, December 15th. The shares were bought at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the purchase, the director now owns 22,000 shares of the company’s stock, valued at $1,370,600. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.23% of the stock is currently owned by company insiders.

Several equities analysts have recently commented on BMY shares. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Tuesday, December 5th. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Monday, December 11th. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price target on the stock. in a research report on Friday, December 22nd. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, Credit Suisse Group set a $62.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, January 22nd. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $66.30.

Shares of Bristol-Myers Squibb Co (BMY) opened at $66.68 on Wednesday. Bristol-Myers Squibb Co has a 12 month low of $51.56 and a 12 month high of $70.05. The company has a market cap of $108,860.00, a P/E ratio of 28.25, a price-to-earnings-growth ratio of 2.08 and a beta of 0.98. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same quarter last year, the business earned $0.63 earnings per share. Bristol-Myers Squibb’s revenue was up 3.9% compared to the same quarter last year. equities research analysts forecast that Bristol-Myers Squibb Co will post 3.21 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be paid a $0.40 dividend. The ex-dividend date is Thursday, April 5th. This represents a $1.60 annualized dividend and a dividend yield of 2.40%. Bristol-Myers Squibb’s payout ratio is currently 67.80%.

COPYRIGHT VIOLATION WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/03/14/bristol-myers-squibb-co-bmy-stake-increased-by-california-public-employees-retirement-system.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.